Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Generation Bio
Biotech
Xoma adds another struggling biotech to its buyout roster
After Generation Bio telegraphed major layoffs this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold.
Fraiser Kansteiner
Dec 16, 2025 11:00am
Former Aurion chief vaults to Valitor—Chutes & Ladders
Oct 24, 2025 8:30am
Generation Bio jettisons 90% of employees, including R&D org
Aug 13, 2025 5:00am
Generation Bio eliminates 40% of staff, including C-suite execs
Nov 29, 2023 8:58am
Moderna pays Generation Bio $76M in lipid nanoparticle collab
Mar 23, 2023 10:58am
Generation Bio shares halved on hemophilia gene therapy setback
Dec 14, 2021 2:30pm
